FDA expands approval of Sunitinib to reduce the risk of kidney cancer returning

November 16, 2017 – The U.S. Food and Drug Administration today approved Sunitinib malate for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back. “This is the first adjuvant treatment approved for patients with renal cell carcinoma … (leggi tutto)